BEAM vs EDIT
BEAM and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $2.84B | $440.77M |
| P/B | 2.66 | — |
| P/S | 20.3x | 10.9x |
| Revenue | $156.03M(TTM) | — |
| Revenue growth (YoY) | 120.0% | 25.4% |
| Net income | -$86.52M(TTM) | — |
| Earnings growth (YoY) | 78.8% | 32.5% |
| EPS, diluted | $-0.69(TTM) | — |
| EBIT margin | -274.6% | -394.9% |
| ROE | -7.5% | -152.0% |
| ROIC | -40.5% | — |
| 1y total return | +53.7% | +15.3% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: BEAM vs EDIT
| 지표 | BEAM | EDIT |
|---|---|---|
| 최종 가치 | $14.7K | $1.0K |
| 총수익률 | +46.6% | -89.7% |
| CAGR | +6.1% | -29.6% |
| 변동성 | 80.1% | 92.6% |
| 샤프 | 0.42 | 0.02 |
| 소르티노 | 0.65 | 0.03 |
| 최대 낙폭 | -89.1% | -98.9% |
공통 거래일 1634일 기준, 2020-02-06 → 2026-08-07 · 무위험수익률 3.87% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)